638 related articles for article (PubMed ID: 14717619)
1. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
Simpson D; Plosker GL
Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
Simpson D; Plosker GL
CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
4. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
6. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
Lee SI; Song DH; Shin DW; Kim JH; Lee YS; Hwang JW; Park TW; Yook KH; Lee JI; Bahn GH; Hirata Y; Goto T; Takita Y; Takahashi M; Lee S; Treuer T
Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.
Christman AK; Fermo JD; Markowitz JS
Pharmacotherapy; 2004 Aug; 24(8):1020-36. PubMed ID: 15338851
[TBL] [Abstract][Full Text] [Related]
9. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
[TBL] [Abstract][Full Text] [Related]
10. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
Takahashi M; Goto T; Takita Y; Chung SK; Wang Y; Gau SS
Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
CNS Drugs; 2010 Jan; 24(1):85-8. PubMed ID: 20030421
[TBL] [Abstract][Full Text] [Related]
12. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
[TBL] [Abstract][Full Text] [Related]
13. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
Davids E; Gastpar M
Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
[TBL] [Abstract][Full Text] [Related]
15. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
Corman SL; Fedutes BA; Culley CM
Am J Health Syst Pharm; 2004 Nov; 61(22):2391-9. PubMed ID: 15581262
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
[TBL] [Abstract][Full Text] [Related]
17. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder.
Kratochvil CJ; Vaughan BS; Harrington MJ; Burke WJ
Expert Opin Pharmacother; 2003 Jul; 4(7):1165-74. PubMed ID: 12831341
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.
Cunill R; Castells X; Tobias A; Capellà D
Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):961-9. PubMed ID: 23813665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]